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Introduction
Rapid Sequence Intubation (RSI) ensures the establishment of protected airway for patients with risk of lung aspiration. It comprises preoxygenation, administration of anesthesia induction drugs, neuromuscular agents and tracheal intubation that preferentially should occur within one minute. Laryngoscopy stimulates sympathetic response, resulting in increase in heart rate, arterial blood pressure, myocardial oxygen consumption and cardiac arrhythmias. [1] Magnesium Sulfate (MS) has been used in anesthesia due to its relevant anesthetic features, such as analgesia, anesthesia and muscle relaxation. [2, 3] MS has two advantages that can be relevant for tracheal intubation. First, it has anti-adrenergic properties for decreasing suprarenal catecholamine release, leading to protection during laryngoscopy and intubation. [3] Second, there is clinical evidence that MS can potentiate effects of neuromuscular blocking agents and provide tracheal intubation conditions without using these agents. [4, 5] The above listed advantages lead us to the assumption that MS can provide enough muscle relaxation for it not be used in association with a neuromuscular blocking agent. Thus, our aim was to determine the efficacy of MS, compared to rocuronium, for orotracheal RSI in adults.
Methods
The randomized, double blind, unicentric, parallel clinical trial was approved by the 
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Heart rate, systolic blood pressure and diastolic blood pressure were registered at four times: before magnesium sulfate or rocuronium administration, after drug administration; and at 1, 3 and 5 minutes after tracheal intubation.
Randomization was performed by throwing six-side dice with three odd and three even faces. When the upper face was even, the participant was allocated into the intervention group (GM), conversely the odd face allocated the participant to the comparison group (GR). Participant allocation was performed after signing the informed consent form and immediately before performing the general anesthesia to enable blind allocation.
Confidentiality of allocation of drugs was assured when medication was prepared and disposed in syringes of the same size, colorless content, with no label or any indication regarding the group the participant was allocated to. Only the individual responsible for preparing syringes knew which group the participant belonged to and that information was unconcealed only after data analysis. The individual responsible for data analysis and participants were blind to group allocation. Inc., San Diego, CA, USA).
Results
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Sixty-eight patients took part in the study and were randomly assigned to two groups ( Fig.1 ). Participants were assessed according to their allocation group. There was no participant loss or exclusion. Data were collected from July 2017 to July 2018.
The demographic features of participant'sage, gender, body mass index, height, weight and physical status classificationdid not show statistical difference as seen on Table 2 . Arterial blood oxygen saturation did not differ between groups, and was not below 99% during any of the analysis moments.
The primary variable or clinical status of tracheal intubation revealed unfavorable results for magnesium use when compared to rocuronium. GM registered 85% (29/34) of patients with poor status, 15% (5/34) with good clinical status and 0% (0/34) with excellent clinical status, as shown in Table 3 . There were no tracheal intubation failures.
Assessment of hemodynamic parameters showed that heart rate did not differ between groups (Table 4) ; however, there was interaction between factors (interaction, p = 0.042; time, p = 0.043; group, p = 0.074); systolic blood pressure showed no statistical difference between groups (Table 5 ) (interaction, p = 0.284; time, p = 0.0005; group, p = 0.114); and diastolic blood pressure did not differ between groups (Table 6) , however, there was interaction between factors (interaction, p = 0.019; time, p = 0.0001; group, p = 0.683). There was statistically significant difference for adverse events, as they occurred in 20% (7/34) of participants in the magnesium sulfate group and 0% (0/34) in the rocuronium group (p = 0.0237; Fischer's test). The adverse event identified in the study was sweating.
Discussion
The study did not show effectiveness of magnesium sulfate as a single agent to promote Participants of both groups received the drugs used in syringes and in no longer than one minute, which may indicate that the time for drug action could have been insufficient. However, other researchers used this same administration protocol without affecting results. Magnesium blood level was not measured, but two aspects need to be taken into account. First, patients had no known predisposing conditions that would lead to changes in magnesium levels, such as hospital bedridden status, diabetes mellitus, alcoholism, medication use or chronic kidney disease. [3] Second, the objective of a clinical trial is to assess its research protocol under conditions similar to those encountered in daily clinical practice, and preoperative verification of magnesium blood levels is not routine workout.
Clinical status for tracheal intubation in the magnesium sulfate group was considered poor in 85% of patients and clinically unacceptable. The result of this study differs from other clinical trials, but the benefit found in other studies can be explained by the use of magnesium sulfate in combination with a neuromuscular blocker. [8, 9] Magnesium sulfate not associated with neuromuscular blocker has already been assessed in another study with positive results, however, there are clinical and design study differences that may explain result disparity in relation to our study, such as: comparison with saline, geriatric age group, use of magnesium infusion and sample size based on low statistical power. [10] We attributed the negative result found in our study to the dose of magnesium sulfate used, which may have been insufficient for the age range and associated surgical disorders. The optimal dose for magnesium sulfate as an agent not associated with a neuromuscular blocker drug has not been established, and there is no consensus to date.
Assessment of hemodynamic parameters showed that systolic blood pressure did not decrease significantly after magnesium sulfate use. The present study cannot reach a definitive conclusion regarding heart rate and systolic blood pressure. A clinical trial assessed the effect of several doses of magnesium sulfate on cardiovascular response to laryngoscopy and intubation, showing a decrease in hemodynamic parameters after MS administration. [8] The dose used in our study has not been shown to be harmful to patients at orotracheal intubation, since adverse events, other than profuse sweating, after drug infusion were not observed. The effect of blunting the hemodynamic response J o u r n a l P r e -p r o o f during tracheal intubation with magnesium sulfate has been shown in other clinical trials. [9] [10] [11] The clinical implication from our results is that the 50 mg.kg -1 dose of MS, in absence of a neuromuscular blocker, is insufficient to ensure acceptable clinical conditions for tracheal intubation. The dose, however, does not lead to hemodynamic instability and may be used to decrease the hemodynamic response to stress in rapid sequence orotracheal intubation. Neuromuscular blockers are recommended to ensure adequate clinical conditions for tracheal intubation.
The main implication for future research is that higher doses need to be assessed to identify if magnesium sulfate can be used unassociated with a neuromuscular blocker. Clinical settings other than those analyzed here, such as patients in another age group, intubation status in elective surgery, and different doses of hypnotics that have potential use for muscle relaxation such as propofol associated with magnesium sulfate for successful tracheal intubation, may also be assessed.
In summary, a 50 mg.kg -1 dose of magnesium sulfate did not provide acceptable clinical conditions for rapid sequence tracheal intubation in adults when compared with rocuronium. Reaction to insertion: c One to two weak contractions or movements for less than 5s.
d More than two contractions and/or movements for more than 5s.
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